| ALX-804-805PF-C100 | 100 µg | 613.00 USD |  |
||
| Do you need bulk/larger quantities? | |||||
| Alternative Name: | Lymphocyte activation gene-3, FDC protein, CD223 |
| Clone: | 11E3 |
| Host: | Mouse |
| Isotype: | IgG1 |
| Immunogen: | Recombinant human LAG-3 (lymphocyte activation gene-3). |
| UniProt ID: | P18627 |
| Source: | Purified from the hybridoma culture supernatant by Protein G Fast Flow Column. |
| Species reactivity: | Human Monkey |
| Specificity: | Recognizes the first N-terminal D1 domain of LAG-3. |
| Applications: | ELISA, ICC, IHC (FS), IP, WB, FUNC |
| Recommended Dilutions/Conditions: | ELISA (capture) Immunoprecipitation (10µg/ml) Western Blot (5µg/ml) Suggested dilutions/conditions may not be available for all applications. Optimal conditions must be determined individually for each application. |
| Application Notes: | Functional Application: Inhibition. |
| Endotoxin Content: | 0.3EU/mg of protein |
| Formulation: | Liquid. In PBS containing 10% glycerol. |
| Handling: | Avoid freeze/thaw cycles. |
| Shipping: | Blue Ice |
| Short Term Storage: | +4°C |
| Long Term Storage: | -20°C |
| Scientific Background: | The lymphocyte activation gene-3 (LAG-3, CD223), a member of the immunoglobulin superfamily (IgSF) related to CD4, binds to the major histocompatibility complex (MHC) class II molecules but with higher affinity than CD4. Several alternative mRNA splice-variants of human LAG-3 have been described, two of them encoding potential secreted forms: LAG-3V1 (i.e. the D1-D2 domains of the protein, 36 kDa) and LAG-3V3 (D1-D3, 52 kDa). The longer form was detected by ELISA in the serum of healthy individuals as well as of tuberculosis patients with a favorable outcome. LAG-3 expression by T cell clones correlated with IFN-γ production, and hence soluble LAG-3 has been suggested as a serological marker of Th1 responses. |
| Regulatory Status: | RUO - Research Use Only |
